Pemvidutide is an investigational once-weekly injection from Altimmune that activates the GLP-1 receptor and the glucagon receptor in a balanced, roughly 1:1 ratio. Its lead program is a Phase 3 trial in MASH, a progressive fatty liver disease. It has also reported company Phase 2 results in alcohol use disorder (RECLAIM) and in obesity (MOMENTUM). No regulator has approved it for any use.
Ask about Pemvidutide
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Balanced GLP-1 / glucagon dual receptor agonist |
| Primary research interest | MASH (Phase 3); alcohol use disorder and alcohol-associated liver disease (Phase 2); obesity (Phase 2 completed) |
| Highest available evidence | Tier 2: placebo-controlled Phase 2 human trials (MOMENTUM, IMPACT, RECLAIM), reported by the developer through press releases and conference presentations. No full peer-reviewed publication was identified for this entry. |
| Human research available | Yes. Phase 2 trials are complete in obesity, MASH and alcohol use disorder. A Phase 3 MASH trial is enrolling. |
| Development status | Investigational. PERFORMA (Phase 3, MASH) began enrolling in August 2026. RESTORE (Phase 2, alcohol-associated liver disease) has finished enrolling. |
| Regulatory status | Not approved anywhere. FDA Fast Track designation for MASH and for alcohol use disorder; FDA Breakthrough Therapy designation for MASH. |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Pemvidutide |
| Alternative names | ALT-801 (code name), pemvidutide acetate |
| Peptide sequence | Synthetic peptide engineered for balanced, approximately 1:1 potency at the GLP-1 and glucagon receptors; full residue-by-residue sequence not independently verified for this entry |
| Molecular formula | C182H275N39O54 |
| Molecular weight | 3873.42 g/mol |
| CAS Registry Number | 2538014-94-5 |
| UNII | A35F525WBG |
| Chemical modifications | Engineered for balanced dual-receptor agonism (GLP-1 and glucagon), fatty-acid conjugation typical of long-acting injectable peptides in this class |
| Peptide class | Dual GLP-1/glucagon receptor agonist |
| Primary biological target | GLP-1 receptor and glucagon receptor (balanced activation) |
| Developer or originator | Altimmune |
| Development status | Phase 3 (MASH); Phase 2 (alcohol use disorder, alcohol-associated liver disease); Phase 2 obesity trial completed; not approved anywhere |
What it is
Pemvidutide (development code ALT-801) is a synthetic peptide that activates two receptors at once: the GLP-1 receptor, which most weight-loss injections target, and the glucagon receptor, which is involved in how the liver handles fat and in energy use. Altimmune designed it so the two actions are roughly equal in strength. That balance separates it from tirzepatide (GLP-1 and GIP) and retatrutide (GLP-1, GIP and glucagon).
Altimmune, a clinical-stage biopharmaceutical company, started with obesity. The MOMENTUM Phase 2 trial reported up to 15.6 percent weight loss at 48 weeks. The company then moved the drug toward liver disease, where the glucagon action is the point rather than a side feature.
That pivot now defines the program. The company’s Phase 2b IMPACT trial in MASH read out in 2025, and PERFORMA, a global Phase 3 trial in MASH with moderate to advanced fibrosis, began enrolling in August 2026. In July 2026 the company reported Phase 2 topline results in alcohol use disorder (RECLAIM), presented in full at the AASLD Liver Meeting on November 9, 2026. A second Phase 2 trial, RESTORE, is testing it in alcohol-associated liver disease and has finished enrolling.
Everything above is investigational. No marketing application has been reported, and every efficacy figure on this page comes from the developer’s own disclosures.
How does it work?
Plain-English explanation
The GLP-1 half works like other drugs in this class: it reduces appetite and slows digestion. The glucagon half is the unusual part. It is believed to raise energy use and to act directly on the liver, helping it burn fat. That is why the same molecule is being tested for weight loss, for fatty liver disease and for liver damage from drinking.
Technical explanation
Pemvidutide is described by its developer as a balanced, roughly 1:1 potency agonist at the GLP-1 and glucagon receptors. Its half-life allows once-weekly dosing. The earlier MOMENTUM obesity trial reported rapid weight loss without a mandatory titration period at its lower doses. Later trials do titrate: RECLAIM stepped from 1.2 mg to 1.8 mg to 2.4 mg, and PERFORMA uses a monthly step-up. Why the program moved away from no-titration dosing is not explained in the sources reviewed.
Potential benefits and research applications
MASH (metabolic dysfunction-associated steatohepatitis)
What is being investigated: whether pemvidutide can clear liver inflammation, reduce scarring and cut liver fat in people with biopsy-confirmed MASH. How the effect might occur: glucagon receptor activity is believed to act on liver fat directly, and GLP-1 activity adds weight loss and better metabolic control.
Evidence: the IMPACT Phase 2b trial enrolled 212 adults with biopsy-confirmed MASH and fibrosis stage F2 or F3. At 24 weeks, MASH resolution without worsening of fibrosis, the primary endpoint, was reached by 59.1 percent (1.2 mg) and 52.1 percent (1.8 mg) of participants against 19.1 percent on placebo (p<0.0001 for both). Fibrosis improvement without worsening of MASH was 31.8 and 34.5 percent against 25.9 percent on placebo, and that difference was not statistically significant. At 48 weeks the company reported significant improvements over placebo in non-invasive fibrosis and liver-health measures, including the ELF score and liver stiffness, plus larger drops in liver fat.
Strength: a placebo-controlled Phase 2b human trial with a significant primary endpoint. Limitation: the biopsy fibrosis endpoint missed significance at 24 weeks, the 48-week figures are non-invasive tests rather than biopsies, and the results come from the company. Whether the drug improves fibrosis in a biopsy-based Phase 3 is the open question PERFORMA is built to answer.
Alcohol use disorder
What is being investigated: whether pemvidutide reduces heavy drinking in adults with moderate to severe alcohol use disorder who are also overweight or obese. How the effect might occur: GLP-1 drugs are thought to act on reward and craving pathways in the brain. The specific contribution of glucagon receptor activity to drinking has not been established.
Evidence: RECLAIM, a 24-week Phase 2 trial in 100 adults, is the first multicenter Phase 2 trial of a glucagon/GLP-1 dual agonist in this condition. Heavy-drinking days per week fell by 4.20 on pemvidutide and 2.75 on placebo, a difference of 1.45 days per week (95% CI 0.58 to 2.32). Full figures are in the research section below.
Strength: randomized, double-blind and placebo-controlled, with a blood marker of alcohol intake (PEth) that moved in the same direction as self-reported drinking. Limitation: both groups improved substantially, the trial ran only 24 weeks, it enrolled only people with a BMI of 25 or higher, everyone also received a monthly computer-based behavioral program, and the results were presented at a conference and have not been peer-reviewed. No Phase 3 trial in alcohol use disorder has been announced in the company releases reviewed.
Alcohol-associated liver disease
RESTORE is a Phase 2 trial of pemvidutide 2.4 mg weekly against placebo for 48 weeks in overweight or obese adults with alcohol-associated liver disease and liver stiffness of 10.0 to 18.5 kPa. It has finished enrolling. No results have been reported.
Weight loss in obesity and overweight
What is being investigated: weight loss from combined GLP-1 and balanced glucagon receptor activity. Evidence: the MOMENTUM Phase 2 trial enrolled 391 adults with obesity or overweight and at least one weight-related condition, without diabetes. Mean weight loss at 48 weeks was 10.3, 11.2 and 15.6 percent at 1.2, 1.8 and 2.4 mg once weekly, against 2.2 percent on placebo, and 32.1 percent of the top-dose group lost 20 percent or more.
Strength: placebo-controlled Phase 2 data presented at a major diabetes conference. Limitation: Phase 2 only, no Phase 3 obesity trial has reported, and the obesity program is no longer the company’s lead focus.
Lean mass preservation
Company-reported body composition data presented at scientific meetings described favorable fat-to-lean loss ratios. A peer-reviewed, full-length publication with complete body composition statistics was not identified for this entry, so specific percentages are not reproduced here.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Pemvidutide is an investigational, unapproved drug. Every dose figure identified for this entry comes from the developer’s own trial disclosures. No independent academic dosing study, and no established community protocol, was identified.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Alcohol use disorder, RECLAIM (Phase 2, results reported) | Subcutaneous | 1.2 mg for 4 weeks, 1.8 mg for 4 weeks, then 2.4 mg | Once weekly | 24 weeks | Registered but unpublished human trial (company-reported, conference presentation) |
| MASH, IMPACT (Phase 2b, results reported) | Subcutaneous | 1.2 mg or 1.8 mg | Once weekly | 48 weeks | Registered but unpublished human trial (company-reported) |
| Obesity or overweight, MOMENTUM (Phase 2, results reported) | Subcutaneous | 1.2 mg, 1.8 mg or 2.4 mg (2.4 mg used a 4-week titration) | Once weekly | 48 weeks | Registered but unpublished human trial (company-reported, conference abstract) |
| MASH, PERFORMA (Phase 3, enrolling, no results) | Subcutaneous | Monthly step-up in one or two steps from 1.2 mg to a trial dose of 1.8 mg or 2.4 mg | Not stated in the sources reviewed | 52-week primary assessment; outcomes follow-up to about 60 months | Registered human trial, no results |
| Alcohol-associated liver disease, RESTORE (Phase 2, enrolled, no results) | Subcutaneous | 2.4 mg | Once weekly | 48 weeks | Registered human trial, no results |
No dose of pemvidutide has been established as safe or effective. The rows describe what company-sponsored trials administered to enrolled participants, not an instruction.
What the reported figures mean
The figure that appears most often is 2.4 mg once weekly. It is the top dose in MOMENTUM, the only dose in RECLAIM and RESTORE, and one of two trial doses in PERFORMA. The MASH program centers on 1.2 mg and 1.8 mg in Phase 2b, with PERFORMA moving to 1.8 and 2.4 mg.
All of these figures trace to one developer, Altimmune. They are not independent confirmations of one another. The trials used different titration approaches: MOMENTUM described no mandatory titration at its lower doses, RECLAIM stepped up every four weeks, and PERFORMA steps up monthly. Dose and schedule were set by trial protocol for different diseases, so a dose in one row does not carry over to another condition.
No animal-to-human conversion is used on this page, and none is supported. What remains unknown is the dose that Phase 3 will carry forward in MASH, whether alcohol use disorder will get its own Phase 3 program, and how any of these regimens perform in people outside a controlled trial.
Amounts studied in human research
| Research objective | Amount studied | Frequency | Duration | Route | Study population | Source |
|---|---|---|---|---|---|---|
| Alcohol use disorder (RECLAIM) | 1.2 mg, 1.8 mg, then 2.4 mg | Weekly | 24 weeks | Subcutaneous | 100 adults, moderate to severe alcohol use disorder, BMI 25 or higher | Altimmune AASLD presentation, Nov 9, 2026 |
| MASH (IMPACT) | 1.2 mg or 1.8 mg | Weekly | 48 weeks | Subcutaneous | 212 adults, biopsy-confirmed MASH, fibrosis F2 or F3 | Altimmune releases, Jun 26, 2025 and Dec 19, 2025 |
| Obesity (MOMENTUM) | 1.2, 1.8 or 2.4 mg | Weekly | 48 weeks | Subcutaneous | 391 adults with obesity or overweight, no diabetes | Altimmune release, 2024; ADA abstract 262-OR |
Amounts studied in animal research
None used on this page.
Practitioner and community-reported protocols
Not consistently reported. Pemvidutide has not been approved anywhere, and this site did not identify an established, sourced practitioner or community dosing pattern for it.
Conflicts and unanswered questions
The Phase 3 dose, the long-term safety profile, and the durability of the alcohol use disorder effect beyond 24 weeks are not yet known. The RECLAIM result needs a full peer-reviewed paper before the exact figures can be treated as final.
Important published research
RECLAIM (alcohol use disorder), Phase 2
Altimmune reported topline results on July 28, 2026 and presented the full data as a late-breaking oral at the AASLD Liver Meeting on November 9, 2026 (presenter Henry R. Kranzler). The trial is registered as NCT06987513.
Design: multicenter, randomized 1:1, double-blind and placebo-controlled, 50 people per arm. Participants had moderate to severe alcohol use disorder, a BMI of 25 or higher, and drank heavily in the 28 days before screening (at least 28 drinks a week for men, 21 for women, with at least 3 heavy-drinking days a week). Pemvidutide went from 1.2 mg for 4 weeks to 1.8 mg for 4 weeks to 2.4 mg for 16 weeks. Everyone received a monthly computer-based behavioral video.
| Measure at week 24 | Placebo | Pemvidutide | Difference |
|---|---|---|---|
| Heavy-drinking days per week, change | down 2.75 | down 4.20 | 1.45 fewer (95% CI 0.58 to 2.32) |
| Reduction of 2 or more WHO risk levels | 34.8% (16 of 46) | 64.4% (29 of 45) | odds ratio 3.3 (95% CI 1.4 to 7.7), p=0.0049 |
| Zero heavy-drinking days | 17.4% (8 of 46) | 42.2% (19 of 45) | odds ratio 3.8 (95% CI 1.4 to 10.4), p=0.0066 |
| PEth (blood alcohol marker), change | up 22.0 ng/mL | down 153.4 ng/mL | 175.4 ng/mL lower (95% CI 91.1 to 259.6), p<0.0001 |
| Percent days abstinent, improvement | 20.5 points | 38.9 points | 18.4 points (95% CI 5.0 to 31.8), p=0.0075 |
| Drinks per drinking day | down 3.8 | down 4.9 | 1.1 fewer, not significant (p=0.203) |
| Body weight, change | up 0.4% | down 8.7% | 9.1 percentage points |
The company reported p=0.0014 for the primary analysis. A sensitivity analysis that treated post-treatment events as missing gave a similar result (difference 1.24 days per week, 95% CI 0.33 to 2.15, p=0.008). Study retention was 91 percent overall, with 80 percent of the pemvidutide group and 78 percent of the placebo group completing treatment.
What it means: the drinking measures and the PEth blood marker pointed the same way, which makes the result harder to explain by self-report alone. It is also true that the placebo group improved a lot, the trial was short, and the result is company-reported and not yet peer-reviewed.
IMPACT (MASH), Phase 2b
212 adults with biopsy-confirmed MASH and fibrosis F2 or F3, randomized 1:2:2 to pemvidutide 1.2 mg, 1.8 mg or placebo weekly. The 24-week topline (June 26, 2025) gave the biopsy results above, with weight loss of 5.0 and 6.2 percent against 1.0 percent on placebo. A supplemental AI-based reading of the biopsies, which the company described as an additional analysis, showed significant fibrosis reductions. The 48-week topline (December 19, 2025) reported:
| Measure at 48 weeks | Placebo | 1.2 mg | 1.8 mg |
|---|---|---|---|
| ELF score, change | up 0.16 | down 0.49 | down 0.58 |
| Liver fat content, reduction | 8.2% | 45.2% | 54.7% |
| ALT, change (IU/L) | down 10.3 | down 37.8 | down 37.4 |
| Weight loss | 0.2% | 4.5% | 7.5% |
| Stopped for an adverse event | 3.5% | 0% | 1.2% |
All drug-versus-placebo differences for ELF, liver fat, ALT and weight loss were reported as p<0.0001. The company also reported no serious or severe treatment-related adverse events and an End-of-Phase 2 meeting with the FDA that aligned on Phase 3 design.
PERFORMA (MASH), Phase 3, ongoing
Announced August 3, 2026. Global, randomized, double-blind, placebo-controlled, in adults with MASH and fibrosis F2 or F3. Cohort 1 (about 990 people) is designed to support accelerated approval on a biopsy endpoint of MASH resolution, fibrosis improvement or both at 52 weeks. Cohort 2 (about 800 people, selected by non-invasive tests) adds safety data. Final approval would rest on liver-related clinical events at about 60 months. The company expects 52-week data in 2029. No results exist.
MOMENTUM (obesity), Phase 2
Figures are in the weight-loss section above. Source: Altimmune release and ADA 2024 abstract 262-OR.
Timing, duration, and research variables
Every trial above used once-weekly subcutaneous dosing. Duration ranged from 24 weeks (RECLAIM) to 48 weeks (MOMENTUM, IMPACT, RESTORE), with PERFORMA built around a 52-week primary assessment. RECLAIM and PERFORMA both titrate upward in steps, so the amount a participant received changed over the first weeks. Whether effects persist after stopping has not been reported in the sources reviewed. There is no evidence-based ideal cycle or time of day.
Combinations and related research
No formally studied combination of pemvidutide with another peptide was identified. In RECLAIM, both arms received the same computer-based behavioral program alongside the drug or placebo. No practitioner or community combination protocols were identified.
What circulates E5
No established community or practitioner dosing protocol was identified. The figures people repeat (1.2, 1.8 and 2.4 mg weekly) trace back to the developer's trials.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
RECLAIM (24 weeks, 50 per arm, placebo versus pemvidutide): gastrointestinal events 34 versus 62 percent, nausea 24 versus 44, constipation 6 versus 26, diarrhea 10 versus 20, vomiting 6 versus 18. Drug-related adverse events led to 5 people (10 percent) stopping pemvidutide and none stopping placebo; reasons were vomiting (two people), constipation, fatigue and a hemorrhoid flare. Serious adverse events: 1 (2 percent) on placebo and 2 (4 percent) on pemvidutide. One serious case of low blood sodium (hyponatremia) was considered possibly related to the drug, and the other serious event in the pemvidutide group was breast cancer. Severe adverse events were 6 percent on placebo and 12 percent on pemvidutide.
IMPACT: discontinuation for adverse events was low (0 percent at 1.2 mg, 1.2 percent at 1.8 mg, 3.5 percent on placebo at 48 weeks), with no serious or severe treatment-related events reported.
MOMENTUM: nausea in 51.5 percent and vomiting in 27.8 percent at 2.4 mg, with 15.5 percent stopping for drug-related adverse events and one serious event (vomiting) at the top dose. No major adverse cardiac events were reported.
The trials are small by drug-approval standards, short, and company-reported. Long-term safety comparable to approved drugs in this class does not exist yet. Pemvidutide is not sold as a legitimate product anywhere, so purity, identity, concentration and sterility cannot be verified for anything offered under its name.
Regulatory and developmental status
Pemvidutide is not approved by any regulator and no marketing application has been reported. MASH: Phase 3 (PERFORMA) enrolling since August 2026, with FDA Fast Track and Breakthrough Therapy designations; the company says the design reflects feedback from the FDA and European regulators. Alcohol use disorder: Phase 2 (RECLAIM) complete, with FDA Fast Track designation; the company has said it plans an End-of-Phase 2 meeting with the FDA in December 2026, and no Phase 3 trial has been announced in the releases reviewed. Alcohol-associated liver disease: Phase 2 (RESTORE) fully enrolled, no results. Obesity: Phase 2 (MOMENTUM) complete, with no Phase 3 obesity trial announced in the sources reviewed.
A designation speeds the regulatory process. It is not an approval and does not confirm the drug works.
Frequently asked questions
What is pemvidutide?
An investigational once-weekly injection from Altimmune that activates the GLP-1 and glucagon receptors in balance. It is in Phase 3 for MASH and is not approved anywhere.
How does it work?
The GLP-1 action reduces appetite. The glucagon action is believed to raise energy use and act on liver fat.
What dosage has been studied?
1.2 mg and 1.8 mg weekly in the MASH Phase 2b trial, 1.2, 1.8 and 2.4 mg weekly in the obesity trial, and a step-up from 1.2 mg to 2.4 mg weekly in the alcohol use disorder trial. These are trial doses, not recommendations.
What dosage commonly circulates online?
No established community protocol was identified. The figures people repeat trace back to the developer’s trials.
How often is it given in trials?
Once weekly by subcutaneous injection.
How long did the trials last?
24 weeks in the alcohol use disorder trial and 48 weeks in the MASH, obesity and alcohol-associated liver disease trials. The Phase 3 MASH trial has a 52-week primary assessment.
Has it been studied in humans for alcohol use disorder?
Yes. RECLAIM enrolled 100 adults for 24 weeks. Heavy-drinking days fell by 1.45 more per week than on placebo, and a blood marker of alcohol intake moved the same way. The results are company-reported and not yet peer-reviewed.
What side effects have been reported?
Mostly gastrointestinal: nausea, constipation, diarrhea and vomiting. In RECLAIM, 10 percent of the pemvidutide group stopped for drug-related reasons.
Is it approved?
No. It has FDA Fast Track and Breakthrough Therapy designations in some indications, which are not approvals.
What remains unknown?
Phase 3 efficacy and safety in MASH, whether the drinking effect lasts beyond 24 weeks, the long-term safety profile, and whether biopsy-confirmed fibrosis improves.
Bottom line
Pemvidutide is interesting because one molecule is being tested in three related problems: fatty liver disease, alcohol use disorder and obesity. The strongest evidence is a placebo-controlled Phase 2b trial in MASH with a significant primary endpoint, and a Phase 2 alcohol trial in which self-reported drinking and a blood marker both moved. The doses behind all of this are trial doses from one developer, mostly 1.2 to 2.4 mg weekly. Nothing in the record is peer-reviewed in full, the MASH fibrosis endpoint missed significance at 24 weeks, and the alcohol trial was short with a large placebo response. It is investigational, not approved anywhere, and Phase 3 in MASH will not report 52-week data until 2029.
Sources
- Altimmune, Inc. Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide. Company press release. Source for the dose arms, weight loss percentages, and adverse event rates in this entry. Altimmune investor release, 2024
- Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity: A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial. Diabetes. 2024;73(Suppl 1):262-OR. Conference abstract presenting the MOMENTUM trial data. ADA 84th Scientific Sessions, abstract 262-OR
- Altimmune's stock sinks on mixed phase 2 MASH results for GLP-1 drug. Fierce Biotech. Independent news coverage describing the MASH trial results as mixed on certain endpoints; used here as the source for calling the MASH result mixed rather than uniformly positive. Fierce Biotech, 2025
- Wikipedia. Pemvidutide. Source for the molecular formula, molecular weight, and CAS number used in this entry; cross-checked against MedChemExpress's product listing for ALT-801. CAS 2538014-94-5
- Altimmune, Inc. Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial. Late-breaking oral presentation, AASLD The Liver Meeting 2026, November 9, 2026. Company presentation, not peer-reviewed. Source for the RECLAIM design, efficacy figures and adverse event rates in this entry. AASLD The Liver Meeting 2026, late-breaker, publication 5013
- Altimmune, Inc. Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder. Company press release, hosted copy. Source for the topline timing and the first company report of the RECLAIM result. Altimmune press release, Jul 28 2026
- Altimmune, Inc. Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH. Company press release. Source for the PERFORMA design, cohorts, dosing, endpoints, designations and expected readout. Altimmune press release, Aug 3 2026
- Altimmune, Inc. Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial. Company press release, hosted copy. Source for the 48-week non-invasive fibrosis, liver fat, weight and discontinuation figures and the End-of-Phase 2 meeting outcome. Altimmune press release, Dec 19 2025
- Altimmune, Inc. Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH. Company press release, hosted copy. Source for the 24-week biopsy endpoints (MASH resolution and fibrosis improvement) and 24-week weight loss. Altimmune press release, Jun 26 2025
Live registry status
These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.
| Trial | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight NCT06987513 | Phase 2 | Completed | Altimmune, Inc. | 100 | Jul 30, 2026 | Jul 31, 2026 |
Compare Pemvidutide with related compounds
Research area: Metabolic and incretin.